The Second Hospital of Tianjin Medical University
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04152499 | |
| A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy. | Pulmonary Arterial Hypertension PAH | Recruiting | Phase 1 / Phase 2 | 2026-07-22 | NCT07593027 | |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-12-16 | NCT05799287 | |
| Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2025-12-08 | NCT06091124 | |
| Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction | cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2025-11-25 | NCT07110415 | |
| A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | Phase 2 | 2025-08-27 | NCT06241846 | |
| A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 1 | 2025-05-11 | NCT06752746 |